e of cure
for all other radical, curative treatments. What is truly alarming is that
the effort to find more cancers by more than doubling the rate of biopsy,
will only serve to increase the devastation that exists today. Ironically,
increasing number of insignificant cancers included for treatment, will
only serve to (falsely) indicate better cure rates for robotic
prostatectomies. Of course, this will only incentivize urologists to treat
even more cancers. Also of concern is the trend is to treat more aggressive
cancers, Gleason 8 and above. In far too many cases, it is not confirmed
prior to actual surgery that the cancer is organ-confined. The number of
failures, exceeding 1,000,000 men, could easily double within the next few
years. What of these men and these families? The only reasonable conclusion
is to discontinue curative treatments such as robotic prostatectomy, for
the majority of positively diagnosed men until proof exists that these
treatments can successfully cure prostate cancer. There is a real concern
that the cure may become more dangerous than the disease. To read the full
article, "Robotic Prostatectomy - A Race to Failure?," go to
http://www.mrisusa.com.
Reference
1. Minimally Invasive Surgery in Urology, Current Opinion in Urology.
18(2):173-179, March 2008, Box, Geoffrey N; Ahlering, Thomas E
2. Robot-Assisted Prostate Surgery Has Possible Benefits, Higher Costs,
By Lisa Esposito, Editor, Health Behavior News Service, August 29, 2005
3. Clinically Insignificant T1 Stage Tumors Of The Prostate,
Konstantinos Stamatiou, Vassilissa Karanassiou, Kavouras Nikolaos, Makris
Vasilios, Lebren Fred, Emmanuel Agapitos: Clinically Insignificant T1 Stage
Tumors Of The Prostate. The Internet Journal of Urology. 2007. Volume 4
Number 2.
'/>"/>SOURCE Diagnostic Center for Disease Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints2.
The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products3.
Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference4.
Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay5.
Hypertension Diagnostics Announces Fiscal Year 2007 Results6.
Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics7.
Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger8.
Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software9.
Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy10.
New peritoneal dialysis diagnostic discovered11.
Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative